DURHAM, NC--(Marketwire - September 08, 2009) - Aldagen, Inc. today announced that Edward L. Field, President & Chief Operating Officer of Aldagen, will be presenting at the Rodman & Renshaw 11th Annual Healthcare Conference. During the presentation, Mr. Field will provide an overview of the company including recent clinical and strategic developments.
The following are specific details regarding Aldagen’s presentation at the conference:
Rodman & Renshaw 11th Annual Healthcare Conference
Date: September 10, 2009
Time: 5:45 PM
Location: New York Palace Hotel, New York, NY
Room: Garrison Salon, 5th floor
About Aldagen, Inc.
Aldagen is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. The company has four product candidates in clinical trials. Aldagen’s most advanced product candidate, ALD-101, is currently in a pivotal Phase 3 clinical trial to evaluate its efficacy in improving umbilical cord blood transplants used to treat inherited metabolic diseases in pediatric patients. The company also has three other products that are currently in, or have recently completed Phase 1 or Phase 1/2 clinical trials: ALD 151 to improve umbilical cord blood transplants used in the treatment of leukemia, ALD-301 to treat critical limb ischemia, and ALD-201 to treat ischemic heart failure. Aldagen’s product candidates consist of specific populations of adult stem cells that the company isolates using its proprietary technology.
For more information, contact:
Ed Field
President and COO
Aldagen
919-484-2571
Email Contact
Michelle Linn
Linnden Communications
508-362-3087
Email Contact
